Bolus fibrinolysis in acute myocardial infarction;Stellenwert der bolus-fibrinolytika zur therapie des akuten herzinfarkts

Deutsche Medizinische Wochenschrift

Volumn 127, Issue 40, 2002, Pages 2083-2086

  Zeymer, Uwe ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANISTREPLASE; FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; RETEPLASE; TENECTEPLASE;

ACUTE HEART INFARCTION; BOLUS INJECTION; DRUG EFFICACY; DRUG INDICATION; FIBRINOLYTIC THERAPY; HUMAN; REVIEW;

CLINICAL TRIALS; CORONARY CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY;

EID: 0037020401     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34511     Document Type: Review

References (31)

1. Anderson JL, Karagounis LA, Califf RM. Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 1996; 78: 1-8
2. Armstrong PW, Granger C, Van de Werf F. Bolus fibrinolysis. Risk, benefit, and opportunities. Circulation 2001; 103: 1171-1173
3. Arntz HR, Tebbe U, Schuster HP, Sauer G, Meyer J. Leitlinien zur Diagnostik und Therapie des akuten Herzinfarkts in der Prähospitalphase. Z Kardiol 2000; 89: 364-372
4. ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction. The ASSENT-2 double blind randomized trial. Lancet 1999; 354: 716-722
5. ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 338: 605-613
6. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R the ISIS-2 Collaborative Group. I. SIS-2: 10-year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous strepto-kinase, oral aspirin, both, or neither. BJM 1998; 316: 1337-1343
7. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, Chernoff R, Christie LG, Feldman RL, Seals AA, Weaver WD for the RAPID-II Investigators. Randomized comparison of coronary thrombolysis avchieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996; 94: 891-898
8. Cannon CP, McCabe CH, Diver DJ et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction. Results of the TIMI 4 trial. J Am Coll Cardiol 1994; 24: 1602-1610
9. Cannon CP, Gibson M, McCabe CH et al. TNK-tissue plasminogen activator compüared with front-loaded alteplase in acute myocardial infarction. Results of the TIMI 10B trial. Circulation 1998; 98: 2805-2814
10. Cannon C. Thrombolytic medication errors: benefits of bolus thrombolytic agents. Am J Cardiol 2000; 85: 17C-22C
11. Cannon CP, Gibson M, Murphy SA, Van de Werf F, McCabe C. Weight-based dosing of thrombolysis. How well do we estimate weigh? How often would this translate into errors with administration of thrombolytic drugs? A comparison of single-bolus TNK with t-PA in TIMI 10B. J Am Coll Cardiol 2001; 37: 323A(Suppl A
12. Coulter SA, McCabe CH, Giugliano RP, Cutler SS, Charlesworth A, Chew P, Cannon CP. Dosing errors and outcomes in patients receiving single bolus compared with bolus + infusion regimens thrombolytic regimens: an InTIME-2 study. Circulation 1999; 100 (Suppl 1); 1-791
13. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322
14. Franzosi MG, Santoro E, De Vita C, Geraci E, Lotto A. Maggioni F. Rovelli F, Santoro L, Tavazzi L, Tognoni G on behalf of the GISSI Investigators. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction. Circulation 1998; 98: 2659-2665
15. Giugliano RP. Antman EM, McCabe CH et al. InTIME-2b: omission of heparin bolus lowers rate of intracranial hemorrhage with lanoteplase. J Am Coll Cardiol 2000; 35 (Suppl); 407A
16. Giugliano RP, McCabe CH, Antaman EM et al. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 2001; 141: 742-750
17. Granger CB, van de Werf F, Armstrong PW et al. Caution needed in interpreting the impact of dosing errors: a case study from ASSENT 2. Circulation 2000; 102 (Suppl II); 11-590
18. Gurwitz JH, Gore JM, Goldberg RJ et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction: participants in the NRMI 2. Ann intern Med 1998; 129: 597-604
19. InTIME-2 Investigators. Intravenous NPA for the treatment of infarcting myocardium early: InTIME-2, a double-blind comparison of single-bolus lanoteplase versus accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21: 2005-2013
20. ISIS 3 Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770
21. Mehta SR, Eikelboom JW, Yusuf S. Risk of intracranial hemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet 2000; 356: 449-454
22. Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989; 14: 1566-1569
23. Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Mäurer W, Limbourg P, Merx W, Haerten K. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC Patency Study (TAPS). J Am Coll Cardiol 1992; 19: 885-891
24. Seyedroudbari A, Kessler ER, Mooss AN, Wundeman RL, Bala M, Hilleman DE. Time to treatment and cost of thrombolysis: a multicenter comparison of tPA and rPA. J Thromb Thrombolysis 2000; 9: 303-308
25. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected myocardial infarction. N Engl J Med 1993; 329: 383-389
26. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1620
27. The GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-1123
28. Touboul P. CAPTIM Study. Vortrag in der Hotline Session I beim ESC-Kongress, Stockholm, 2.9.01
29. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21: 1391-1395
30. White HD, Van de Werf FJJ. Thrombolysis for acute myocardial infarction. Circulation 1998; 97: 1632-1646
31. Zeymer U, Neuhaus KL. New Thrombolytic agents. Humana Press, Totowa, USA, In: C.P. Cannon (Editor): Management of Acute Coronary Syndromes. 1998: 243-265